More about

Atezolizumab

News
July 21, 2020
1 min read
Save

Triple therapy has comparable results in relapsed/refractory B-cell lymphoma

Atezolizumab, obinutuzumab and venetoclax combined produced a durable response in relapsed/refractory diffuse large B-cell lymphoma but presented best in low tumor burden cases, according to a poster presented at ASCO20 Virtual Scientific Sessions.

News
July 14, 2020
4 min read
Save

Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma

Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma

Atezolizumab plus platinum-based chemotherapy prolonged PFS as first-line therapy for patients with metastatic urothelial carcinoma, according to results of the randomized phase 3 IMvigor130 trial published in The Lancet.

News
July 01, 2020
4 min read
Save

Growing treatment landscape in SCLC spurs excitement

Growing treatment landscape in SCLC spurs excitement

The treatment landscape for relapsed and refractory small cell lung cancer is an area ripe for investigation.

News
June 25, 2020
4 min read
Save

FDA approves four NSCLC regimens

FDA approves four NSCLC regimens

The FDA approved four regimens for non-small cell lung cancer since mid-May.

News
June 19, 2020
1 min watch
Save

VIDEO: Tiragolumab plus atezolizumab confers benefit for certain patients with NSCLC

VIDEO: Tiragolumab plus atezolizumab confers benefit for certain patients with NSCLC

In this video, Julia K. Rotow, MD, medical oncologist at Dana-Farber Cancer Institute, shared her thoughts on data from the CITYSCAPE trial presented during the ASCO20 Virtual Scientific Program.

News
June 18, 2020
1 min read
Save

Atezolizumab regimen improves outcomes in early triple-negative breast cancer

Atezolizumab regimen improves outcomes in early triple-negative breast cancer

The addition of atezolizumab to chemotherapy improved pathologic complete response among patients with early triple-negative breast cancer, according to the agent’s manufacturer.

News
June 15, 2020
3 min watch
Save

VIDEO: Novel immune targets in lung cancer ‘generate excitement’

VIDEO: Novel immune targets in lung cancer ‘generate excitement’

In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, discussed results from KEYNOTE-604.

News
June 02, 2020
2 min read
Save

FDA approves immunotherapy regimen for advanced liver cancer

FDA approves immunotherapy regimen for advanced liver cancer

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

News
June 01, 2020
4 min read
Save

Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma

Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma

Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

News
May 22, 2020
5 min read
Save

Immunotherapy or TKI: Debating the best HCC treatment options

Immunotherapy or TKI: Debating the best HCC treatment options

Thomas A. Abrams, MD, senior physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, spoke with Healio about treatment options for patients with hepatocellular carcinoma. He discusses first-line treatment, guidance on aspirin use and important, recent FDA approvals.

View more